ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

UCB, Inc. (UCBJF.PK) Gets Japan Clearance for Two New Drugs


12/27/2012 7:59:13 AM

Belgian pharmaceutical company UCB has secured two regulatory clearances in Japan, further cementing its worldwide shift to a new generation of drugs. The company said in a statement on Tuesday that the Japanese Ministry of Health, Labour and Welfare had approved UCB's Neupro patch to treat Parkinson's disease and moderate-to-severe Restleg Legs Syndrome in adults. Otsuka Pharmaceutical has the exclusive rights for developing and marketing Neupro in Japan, with UCB responsible in all other regions worldwide. Neupro is available in 35 countries. In a separate statement on Tuesday, UCB said its drug Cimzia had been approved in Japan for treatment of rheumatoid arthritis in adults.

Read at Reuters


 Read Article at  Related Companies  News Categories
Reuters
UCB, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES